cyrilzakka/clinical-trials huggingface dataset:
Effect of Different Antihypertensive Treatment on Serum Uric Acid in Newly Diagnosed Hypertensive Patients

Assessment of the influence of different antihypertensive drugs on serum uric acid in newly diagnosed hypertension patients.

Hypertension is the most common condition seen in primary care and leads to myocardial infarction, stroke, renal failure, and death if not detected early and treated appropriately.

Thiazide-type diuretics, angiotensin-converting enzyme (ACE) inhibitors and some of angiotensin-II receptor blockers (ARB) were reported to reduce renal excretion of urate and increased serum uric acid levels, Beta-blockers also elevate serum uric acid levels.

Hyperuricemia is a risk factor for cardiovascular diseases. Hyperuricemia was found to correlate with hypertension excluding the influence of other factors such as age and renal function. Furthermore, many studies found that hyperuricemia was independently associated with cardiovascular events in patients treated with antihypertensive drugs.

It is important to control serum uric acid levels in hypertensive patients treated with antihypertensive drugs in order to reduce the risk of gout and cardiovascular events. There is a gap in knowledge in studies showing the effect of antihypertensive drugs on serum uric acid in newly diagnosed hypertensive patients.

Eligibility Criteria:
Inclusion Criteria:

* All newly diagnosed hypertensive patients aged 30 years old and above will be invited to participate in this study

Exclusion Criteria:

1. Patients below 30 years old.
2. Patients with kidney disease.
3. Patients who are taking medications known to increase SUA as (Thiazide and Loop diuretics, Salicylates, Cyclosporin use) or decrease the level of uric acid in the urine as (Allopurinol, Febuoxstate).
Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France

No structured organization for ovarian first line management emerges in France. Management across France seems to depend on regional contexts.

Regions display no specific organization or delineate regional network for the ovarian cancer management or report centralized management revolving around referent centers. These different templates present a major problem in identifying differences, costs and benefit.

To deal with this issue the Investigators propose a health economic evaluation based on cost-effectiveness analyses, completed with a budget impact analysis. This study will investigate the cost-effective management of patients with initial ovarian cancer using databases representative of different parts of French territories.


Eligibility Criteria:
Inclusion Criteria:

* Ovarian epithelial cancer initially diagnosed in 2012
* Age \> 18 years old
* Residency in France (Rhône-Alpes region, District of Calvados and Cotes d'Or)
* First-line ovarian epithelial cancer

Exclusion Criteria:

* Relapsed ovarian epithelial cancer
* Non epithelial ovarian cancer
Cervical Spine Strengthening Exercises Versus Kendall Exercises in Patients With Forward Head Posture.

To compare the effects of targeted cervical spine strengthening exercises and Kendall exercise in patients with forward head posture

Studies have evaluated the effect of Kendall's exercises and found it effective for recovery. Studies have also concluded that targeted strengthening of flexors reverse the symptoms. The purpose of this study will elaborate either there is a difference in time taken to achieve normal head alignment between a targeted muscle that is prone to weakness or a technique that involves strengthening of weakened muscle plus stretching of shortened muscles. As there is a vast variety of correcting exercise program in the literature, the decision to choose the best option may be challenging. This study may help physiotherapists to apply treatment that is directly directing the main culprit.

Eligibility Criteria:
Inclusion Criteria:

* Both genders
* Age 20-40 years with no signs of degeneration.
* Individuals having cranio-vertebral angle less than 50
* Those who have not gone under rehabilitation for last 6 months
* Those who are computer users for more than 3 hours a day or more.

Exclusion Criteria:

* Spinal trauma
* Musculoskeletal abnormality in the cervical spine
* Rheumatologic disorders
* Any bony or soft tissue systemic disease
* Congenital defects
* Disc pathology
Photobiomodulation Therapy (PBMT) in Patients With Low Back Pain (LBP)

Low back pain (LBP) is a highly prevalent condition worldwide and the leading cause of years lived with disability. In most cases, the specific pathological cause remains unidentified; therefore, the term non-specific low back pain is commonly used for such cases. Many non-pharmacological therapies are available for the treatment of low back pain aiming to reduce pain and disability. Among these options, photobiomodulation therapy (PBMT) it seems to be an interesting alternative. PBMT is a non-thermal and non-invasive clinical treatment, which has shown effects in decreased pain, modulation of inflammatory process, and tissue repair in musculoskeletal disorders. Therefore, the aim of this project is to evaluate the effects of the PBMT against placebo on pain intensity in patients with chronic non-specific low back pain.

To achieve the proposed objective, it will be performed a randomized, triple-blind (patients, therapists, and outcome assessors), placebo-controlled trial.

Seventy-two patients with chronic non-specific low back pain will be randomly allocated to two treatment groups: 1. Active PBMT or Placebo PBMT.

In both groups, six treatment sessions will be performed twice a week (at the same time of the day), with intervals of three or four days between sessions, during three-week period. The patients will be treated by a blinded therapist.

The outcomes will be obtained at stabilization phase (during 2 weeks), baseline, end of treatment, 24, 48 and 72 hours after the last treatment session, and 7 days after conclusion of treatment. The data will be collected by a blinded assessor.

Statistical analyzis:

* The Fischer's Exact Test will be conducted to compare the proportion of successes between groups.
* The Unpaired t-test will be used for demographic data.
* Repeated measures ANOVA will be performed to analyze pain intensity. The level of statistical significance will be set at p\<0.05.

Eligibility Criteria:
Inclusion Criteria:

* Patients with chronic non-specific low back pain, with symptoms present for at least three months;
* Patients with a pain intensity of at least 50mm (measured by a 0-100 mm Visual Analog Scale);

Exclusion Criteria:

* Serious spinal pathologies (such as fractures, tumors, inflammatory, and infectious diseases);
* Patients who used local corticosteroids and/or botulin toxin injection for pain relief within the prior 30 days of the beginning of the study;
* Chronic pain diseases as fibromyalgia and diabetic type 1;
* Neuropathic pain;
* Previous spinal surgery in the past 12 months;
* Cancer patients;
* Pregnancy or breast feeding.
First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-01-097 in patients with advanced solid tumors.


Eligibility Criteria:
Inclusion Criteria:

* Advanced solid tumor
* Measurable disease, per RECIST v1.1
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* Adequate organ function

Exclusion Criteria:

* Has not recovered \[recovery is defined as NCI CTCAE, version 5.0, grade ≤1\] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements
* Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of UCT-01-097
* Progressive or symptomatic brain metastases
* Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection
* History of phosphate or calcium disorder
* History of significant cardiac disease
* History or current evidence/risk of retinopathy
* History of myelodysplastic syndrome (MDS) or AML
* History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. A history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate cancer with a Gleason score less than or equal to 6, are also not excluded
* If female, is pregnant or breastfeeding
Pre-operative Blood Lipid Level and Post-operative Major Adverse Cardiac Event

Whether the pre-operative blood lipid level and post-operative cardiovascular events is associated is unknown. This study is to find out the main blood lipid and relative protein level change and the post-operative cardiovascular events occurrence.

The participants collected data from their hospital.Patients under going non-cardiac surgery were collected. Data of Triglycerides, cholesterol, Low-density lipoprotein and High-density lipoprotein were collected perioperatively. The postoperative major cardiovascular and cerebral events were also identified and collected. Other data including perioperative information and surgeries and anesthesia data were gathered.

Logistic regression models were built and selected. Independent risk factors relative to postoperative major cardiovascular and cerebral events were screened and identified. different levels of Triglycerides, cholesterol, Low-density lipoprotein and High-density lipoprotein were analysed.

Eligibility Criteria:
Inclusion Criteria:

* non-cardiac surgery patients with preoperative blood lipid tests

Exclusion Criteria:

* electronic records missing or peri-operative data missing
Impact of Travel Neck Pillow Use on Neck Comfort and Mobility After Thyroidectomy

This study aims to evaluate the effectiveness of U-shaped travel neck pillow use in improving cervical comfort, reducing neck pain and stiffness, and enhancing cervical range of motion in adults undergoing total thyroidectomy surgery. It is the first randomized controlled trial in Turkey to examine the use of a travel neck pillow as a non-pharmacological intervention during the immediate postoperative period (day 0).

The study will be conducted at Erciyes University Gevher Nesibe Hospital between December 5, 2024 and June 5, 2025. Participants will be randomly assigned to either the pillow group or the control group. Those in the pillow group will use a U-shaped neck pillow for the first 24 hours after surgery while at rest.

Outcomes will be assessed using the Visual Analog Scale (VAS) for pain and comfort, the McGill Pain Questionnaire for pain localization and intensity, and goniometric measurements of cervical range of motion. Data will be collected preoperatively and at 24 hours postoperatively.

This study is expected to provide clinical evidence supporting the use of travel neck pillows to improve postoperative comfort and mobility, offering a simple and cost-effective nursing intervention for thyroidectomy recovery.


Eligibility Criteria:
Inclusion Criteria:

* Scheduled to undergo elective total thyroidectomy

Classified as ASA physical status I or II

Aged 18 years or older

No communication impairments

Willing to participate and provide informed consent

Exclusion Criteria:

* Patients with a previously diagnosed condition in the cervical spine region prior to surgery

Patients who have previously undergone thyroidectomy
Selective Axillary Lymph Node Dissection Vs Complete Axillary Dissection: A Randomised Clinical Trial to Assess the Prevention of Lymphedema in Breast Cancer Treatment

This is a pilot study at the National Cancer Institute (INT) of Milan evaluated the feasibility of selective axillary dissection (SAD) which preserved the lymphatic drainage of the arm. Lymph nodes draining the arm are identified following radiotracer injection and lymphoscintigraphy, a technique called axillary reverse mapping (ARM). SAD was found feasible in 75% of patients. Furthermore only 9% had BCRL after SAD compared to 33% after axillary lymph node dissection (ALND).

To evaluate the efficacy, safety and cost reduction of SAD compared to standard ALND, we propose a prospective 2-arm randomised trial. The control arm consists of patients randomized to ALND, the study arm consists of patients randomized to SAD.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with operable breast cancer who are candidates for ALND, irrespective of the type of breast surgery performed or adjuvant treatments administered.
* Patients who sign the informed consent form after explanation of trial aims by a senologist involved in the study.
* Patients able to attend INT for regular follow-up as required by study protocol.

Exclusion Criteria:

* Massive axillary metastasis (N2 AJCC).
* Previous surgery to controlateral axillary region.
* Previous radiotherapy to ipsilateral or controlateral regional lymph nodes.
* Non compliance with any inclusion criterion.
Functional Outcome Following Surgical Treatment of Patients With Sternoclavicular Joint Infection

The Sternoclavicular joints (SCJ) represents an important factor in stability of shoulder joint. Its influence and its function is important for the functionality of the shoulder. SCJ infection is a rare condition and remains often mistreated and potentially life threatening.

This study is to assess the cases treated at the University Hospital Basel with a surgical approach of extended resection of the SCJ. One prospective follow-up visit inclusive one physical examination per patient will be performed to evaluate the long-term functional results of arm, shoulder, hand function with the QuickDASH questionnaire.


Eligibility Criteria:
Inclusion Criteria:

* Patient assigned and treated at the Department of Thoracic Surgery, University Hospital Basel (USB)
* At hospital admission diagnosed with clinical characteristics of sternoclavicular joint infection
* Surgical treatment of extended SCJ resection received
* Signed written informed consent according to ICH-GCP regulations prior to initiation of any protocol-specific activities/procedure
* Patients who died will be included if a signed USB general research consent is available

Exclusion Criteria:

* Isolated sternal or clavicular infection
* Patients received other surgery than extended SCJ resection at USB thoracic surgery
* Inability to follow procedures or insufficient knowledge of language (German/French) or inability to give consent
* Patients who have clearly stated that they would not agree in providing their clinical data for scientific purposes
Long-term Extension of GTX-102 in Angelman Syndrome

The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman Syndrome (AS)

This study is a phase 3, long term extension (LTE) which is open to participants rolling over from a prior GTX-102 clinical study. The LTE study will evaluate the long-term safety and efficacy of GTX-102 in participants with AS.

Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent from parent(s) or legal guardian(s).
* Prior participation in a clinical trial with GTX-102; the timing for the roll-over into this study from a prior GTX-102 study is based on the Investigator and Ultragenyx Medical Monitor's approval.
* From the time of informed consent through the end of the study and for at least 6 months after the final dose of GTX-102, females of childbearing potential who are sexually active must use highly effective contraception or abstinence. Males are able to participate if they agree to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods during the study and for at least 3 months after the final dose of GTX-102.

Exclusion Criteria:

* Known hypersensitivity to GTX-102 or its excipients that, in the judgment of the Investigator, places the subject at increased risk for adverse effects.
* Pregnant or breastfeeding or planning to become pregnant (self or partner) at any time during the study
Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum

The use of a new generation low molecular weight heparin (Bemiparin)and the well known LMWH (Enoxaparin) after Caesarean sections and vaginal deliveries in a risky group patients for venous thrombosis.

Venous thromboembolism (VTE) is the leading cause of maternal mortality and morbidity in the developed and developing world. Pulmonary embolism and deep vein thrombosis are the two components of a single disease called deep vein thrombosis (DVT). Pregnancy associated with an average 5 to 10 fold increase in the risk of VTE compared with non-pregnant women. The highest incidence occurring during the post partum period. There are many researches done a broad on the effect of LMWH to decrease the incidence of VTE after Caesarean section using the two LMWH (Enoxaparin and Bemiparin) alone but not in one research comparing both of them alone and both together against a control group. Also according to our knowledge there are no published literature on thromboprophylaxis after vaginal delivery

Eligibility Criteria:
Inclusion Criteria:

* Presence of risk factors for venous thromboembolism
* Any parity
* Mode of delivery:vaginal, Emergency and Elective Caesarean section
* No any contraindications for Heparin

Exclusion Criteria:

* Active antenatal or postpartum vaginal bleeding.
* Placenta previa
* Thrombocytopenia
* Sever renal or liver diseases
* Uncontrolled sever hypertension
* Any patient who is already on Heparin during pregnancy
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)

A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromegaly.


Eligibility Criteria:
Inclusion Criteria:

1. Male and female subjects ≥18 years of age
2. Confirmed diagnosis of acromegaly and either medically naïve, not currently treated, or willing to washout during the study screening period.
3. Females must be non-pregnant and non-lactating, and either surgically sterile, post-menopausal, or using effective method(s) of birth control
4. Willing to provide signed informed consent

Exclusion Criteria:

1. Pituitary radiation therapy within 3 years of Screening
2. Prior treatment with paltusotine
3. History of ineffective or intolerance to octreotide or lanreotide
4. History or presence of malignancy except adequately treated basal cell and squamous cell carcinomas of the skin within the past 5 years
5. Use of any investigational drug within the past 30 days or 5 half-lives, whichever is longer
6. Known history of HIV, hepatitis B, or active hepatitis C
7. History of alcohol or substance abuse in the past 12 months
8. Any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this study
9. Cardiovascular conditions or medications associated with prolonged QT or those which predispose subjects to heart rhythm abnormalities
10. Subjects with symptomatic cholelithiasis
11. Subjects with clinically significant abnormal findings during the Screening Period, or any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardize the subject's safety or ability to complete the study
12. Subjects currently or previously using pegvisomant or cabergoline (within 16 weeks prior to Screening) or pasireotide LAR (within 24 weeks prior to Screening)
Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

The purpose of this study is to determine the safety and tolerability of MS-R001 at escalating doses in patients with diabetic macular edema secondary to diabetic retinopathy


Eligibility Criteria:
Inclusion Criteria include but are not limited to:

* Diagnosed with diabetes mellitus
* Visual acuity of 20/40 to 20/200 in study eye

Exclusion Criteria include but are not limited to:

* Any other ocular disease that could compromise vision in the study eye
* Intraocular surgery of the study eye within 90 days prior to study start
* Capsulotomy of the study eye within 30 days prior to study start
Anaerobic Antibiotic Usage for Pneumonia in the Medical Intensive Care Unit

Observation of prescription usage of anaerobic antibiotics for patients admitted to the ICU with pneumonia.

Pneumonia is a common admitting diagnosis in the intensive care unit (ICU). When aspiration is suspected, antibiotics to cover anaerobes are frequently used , but in the absence of clear risk factors, current guidelines have questioned their role. It is unknown how frequently these guidelines are followed.

Eligibility Criteria:
Inclusion Criteria:

* ICU patients with diagnosis of pneumonia

Exclusion Criteria:

* patients with abdominal infections such as c diff.
Quantitative Genioglossal Muscle Strength in Obstructive Sleep Apnea (OSAS)

Quantitative Genioglossal muscle strength in Obstructive Sleep Apnea (OSAS) defined in the clinical spectrum of subjects with Snoring Disturbance, Oral Appliance Therapy Responsive, and CPAP Responsive

To describe by statistical analysis the normal distribution domain of genioglossus muscle strength in each of the four clinical stages of Sleep Apnea; and, by regression analysis, to explore the possibility of an inverse relationship between decreasing genioglossus strength and progression of the clinical stages of OSAS.

1.3. To test the hypothesis that a "subpopulation of subject" exists within the clinical spectrum of OSAS, in whom decreasing strength of the genioglossus muscle may represent a common element in spite of differing possible pathophysiologic pathways leading to Obstructive Sleep Apnea in man. 1.4. The major hypothesis of this proposal is thus that "Genioglossal Strength is inversely correlated with Obstructive Sleep Apnea Pathology."

Eligibility Criteria:
Inclusion Criteria:

* Age 20-40 years inclusive BMI 18-25 Non-smoking history and no current use for a minimum of 6 months No smokeless tobacco products (including e-cigarettes) for a minimum of 6 months No sleep snoring reported by subject and by bedroom "companion" Self-described as active/athletic (i.e. regular hikes, walks, jogging, running, active Sports, such as volleyball, soccer, etc.) Self-described as healthy, with no known disease or recent illness Self-completed Epworth Sleepiness Scale of \<6 (Johns, MW, A new method for Measuring daytime sleepiness: the Epworth Sleepiness Scale; SLEEP 14:450-5, 1991). Physical Examination Mallampati Score of Class 1 (Nuckton, TJ, et al: Physical

Examination: Mallampati Score as an Independent Predictor of OSAS; SLEEP 29:

903-908, 2006).

Exclusion Criteria:

-